Palbociclib

What is Palbociclib?[edit | edit source]

Palbociclib (Ibrance) is a kinase inhibitor used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

This medicine is used to treat:

hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) in combination with:
letrozole as the first hormonal based therapy in women who have gone through menopause, or
fulvestrant in women with disease progression following hormonal therapy.

Palbociclib (pal" boe sye' klib) is an orally available, specific inhibitor of cyclin-dependent kinases that is used in combination with aromatase inhibitors in the therapy of postmenopausal women with metastatic breast cancer that is positive for the estrogen receptor (ER+), but negative for human epidermal growth factor receptor 2 (HER2-).
The cyclin kinases 4 and 6 regulate the cellular transition from the G1 to the S phase of the cell cycle.
Inhibition of this transition blocks the progression of the cell cycle and results in growth arrest in rapidly dividing cells.
The addition of palbociclib to letrozole or fulvestrant (aromatase inhibitors) therapy of metastatic breast cancer (ER+, HER2-) in postmenopausal women was associated with a prolongation of disease free survival.

Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole). Avoid grapefruit or grapefruit juice during Ibrance treatment. If coadministration of Ibrance with a strong CYP3A inhibitor cannot be avoided, reduce the dose of Ibrance.
Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine, enzalutamide, and St John's Wort).
The dose of the sensitive CYP3A substrate with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus and tacrolimus) may need to be reduced as Ibrance may increase their exposure.

Recommended Dosage:

The recommended dose of Ibrance is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.
When coadministered with palbociclib, the recommended dose of letrozole is 2.5 mg taken once daily continuously throughout the 28-day cycle.
When coadministered with palbociclib, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, 29, and once monthly thereafter.
If patients must be coadministered a strong CYP3A inhibitor, reduce the Ibrance dose to 75 mg once daily.

Administration

Take Ibrance exactly as your healthcare provider tells you.
Take Ibrance with food.
Swallow Ibrance capsules whole. Do not chew, crush or open Ibrance capsules before swallowing them.
Do not take any Ibrance capsules that are broken, cracked, or that look damaged.
Avoid grapefruit and grapefruit products during treatment with Ibrance. Grapefruit may increase the amount of Ibrance in your blood.
Do not change your dose or stop taking Ibrance unless your healthcare provider tells you.
If you miss a dose of Ibrance or vomit after taking a dose of Ibrance, do not take another dose on that day. Take your next dose at your regular time.
If you take too much Ibrance, call your healthcare provider right away or go to the nearest hospital emergency room.

This medicine is available in fallowing doasage form:

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

Ibrance may cause serious side effects, including:

Neutropenia may occur. Monitor complete blood count prior to start of Ibrance therapy and at the beginning of each cycle, as well as on Day 14 of the first 2 cycles, and as clinically indicated.
Pulmonary embolism has been reported at a higher rate in patients treated with Ibrance plus letrozole. Monitor patients for signs and symptoms of pulmonary embolism and treat as medically appropriate.
Ibrance Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

Management for overdosage:

There is no known antidote for Ibrance.
The treatment of overdose of Ibrance should consist of general supportive measures.

Ibrance can cause fetal harm when administered to a pregnant woman .
There are no available data in pregnant women to inform the drug-associated risk.

Active ingredient: palbociclib
Inactive ingredients: Microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard gelatin capsule shells.

Palbociclib Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.